NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Applied Data Research

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Product Evolution in Drugs for Chronic Pain Management Creating Treatment Options - Applied Data Research analyzes the potential for evolving dosing and formulation technology - AppliedData.org
Product Evolution in Drugs for Chronic Pain Management Creating Treatment Options

 

NewswireTODAY - /newswire/ - Amherst, NH, United States, 2011/05/12 - Applied Data Research analyzes the potential for evolving dosing and formulation technology - AppliedData.org.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Individuals suffering from ailments that include cancer, back problems, osteoarthritis and orthopedic injury are subject to moderate-to-severe levels of chronic pain. Orally delivered pain products may not provide rapid relief and typically demonstrate considerable patient-to-patient variability in absorption. Injectable formulations of pain products provide rapid and effective pain relief, but administration often requires professional assistance or hospitalization.

Recently approved and development-stage pain products formulated for less frequent dosing offer the potential to provide significant medical benefits over oral and injectable formulations by combining patient convenience and ease of use with the onset of pain relief at potency levels equivalent to injectable delivery routes. These products represent the early phase of a new generation in the evolution of chronic pain management. As the incidence and prevalence of chronic pain increase with aging populations, pain drug products that evolve to meet the demands of a changing market will be well-positioned to capitalize on these trends.

A detailed analysis of evolving drug product strategies for chronic pain management and the market opportunities these advances are creating are contained in a new and comprehensive report from Applied Data Research. The report - Product Evolution in Chronic Pain Management: Evolving Formulations, Dosage Forms, Market Factors and Prospects - provides analysis, assessments, profiles and forecasts that provide a comprehensive view of this evolving healthcare segment.

About Applied Data

Applied Data Research (applieddata.org) is a healthcare technology consulting firm focused on market strategies, product commercialization, venture development, and market research. We assist market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Because we make it our responsibility to cut through the clutter and the noise of modern information gathering and assessment, company decision makers turn to us for the answers they need to achieve their objectives.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Applied Data Research

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Product Evolution in Drugs for Chronic Pain Management Creating Treatment Options

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Greg Stone - AppliedData.org 
603-718-4564 grstone[.]applieddata.org
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Applied Data Research securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Applied Data Research / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

NEC Selected by AMED for Design of A Universal Vaccine that is Effective Against Influenza Virus Strains
BostonGene, NEC and JIP Form Joint Venture in Japan
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib
US FDA Approves Ipsen’s Sohonos™ (palovarotene) Capsules, the First and Only Treatment for People with Fibrodysplasia Ossificans Progressiva
SCHOTT Pharma Strengthens Leading Position in the First Year as Stand-alone Company
Frost & Sullivan Awarded Duopharma Biotech with the 2022 Malaysian Company of the Year Award
Duopharma Biotech Applauded by Frost & Sullivan for Providing Innovative Healthcare Solutions in the Malaysian Market
Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP
U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome
DNAnexus® Applauded by Frost & Sullivan for Supporting Better Clinical Decision-making and More Effective Therapies
Ipsen to Present New Bylvay® (odevixibat) Data At ESPGHAN Congress, Showcasing Commitment to Furthering Treatment for Rare Cholestatic Liver Diseases
SCHOTT Pharma Launches Prefillable Syringes (PFS) for Deep-cold Drugs
ANDRITZ Introduces Comprehensive Solutions to Produce Alternative Proteins
DSM Agrees Terms to Acquire Postbiotics Pioneer Adare Biome
NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented At AACR 2023

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  JobsWare.com





 
  ©2005-2023 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)